Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy - PubMed (original) (raw)
. 2006 Oct;291(4):H1545-53.
doi: 10.1152/ajpheart.01124.2005. Epub 2006 Apr 21.
Affiliations
- PMID: 16632544
- DOI: 10.1152/ajpheart.01124.2005
Free article
Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy
Jyothish B Pillai et al. Am J Physiol Heart Circ Physiol. 2006 Oct.
Free article
Abstract
Poly(ADP-ribose) polymerase-1 (PARP), a chromatin-bound enzyme, is activated by cell oxidative stress. Because oxidative stress is also considered a main component of angiotensin II-mediated cell signaling, it was postulated that PARP could be a downstream target of angiotensin II-induced signaling leading to cardiac hypertrophy. To determine a role of PARP in angiotensin II-induced hypertrophy, we infused angiotensin II into wild-type (PARP(+/+)) and PARP-deficient mice. Angiotensin II infusion significantly increased heart weight-to-tibia length ratio, myocyte cross-sectional area, and interstitial fibrosis in PARP(+/+) but not in PARP(-/-) mice. To confirm these results, we analyzed the effect of angiotensin II in primary cultures of cardiomyocytes. When compared with PARP(-/-) cardiomyocytes, angiotensin II (1 microM) treatment significantly increased protein synthesis in PARP(+/+) myocytes, as measured by (3)H-leucine incorporation into total cell protein. Angiotensin II-mediated hypertrophy of myocytes was accompanied with increased poly-ADP-ribosylation of nuclear proteins and depletion of cellular NAD content. When cells were treated with cell death-inducing doses of angiotensin II (10-20 microM), robust myocyte cell death was observed in PARP(+/+) but not in PARP(-/-) myocytes. This type of cell death was blocked by repletion of cellular NAD levels as well as by activation of the longevity factor Sir2alpha deacetylase, indicating that PARP induction and subsequent depletion of NAD levels are the sequence of events causing angiotensin II-mediated cardiomyocyte cell death. In conclusion, these results demonstrate that PARP is a nuclear integrator of angiotensin II-mediated cell signaling contributing to cardiac hypertrophy and suggest that this could be a novel therapeutic target for the management of heart failure.
Similar articles
- Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity.
Pillai JB, Isbatan A, Imai S, Gupta MP. Pillai JB, et al. J Biol Chem. 2005 Dec 30;280(52):43121-30. doi: 10.1074/jbc.M506162200. Epub 2005 Oct 5. J Biol Chem. 2005. PMID: 16207712 - AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy.
Liu M, Li Z, Chen GW, Li ZM, Wang LP, Ye JT, Luo HB, Liu PQ. Liu M, et al. Mol Cell Endocrinol. 2014 Jul 5;392(1-2):14-22. doi: 10.1016/j.mce.2014.05.010. Epub 2014 May 21. Mol Cell Endocrinol. 2014. PMID: 24859603 - Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure.
Pillai JB, Russell HM, Raman J, Jeevanandam V, Gupta MP. Pillai JB, et al. Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H486-96. doi: 10.1152/ajpheart.00437.2004. Epub 2004 Sep 16. Am J Physiol Heart Circ Physiol. 2005. PMID: 15374823 - Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ, Bourgeois M, Harbison RD. Henning RJ, et al. Cardiovasc Toxicol. 2018 Dec;18(6):493-506. doi: 10.1007/s12012-018-9462-2. Cardiovasc Toxicol. 2018. PMID: 29968072 Review. - Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation.
Erdélyi K, Bakondi E, Gergely P, Szabó C, Virág L. Erdélyi K, et al. Cell Mol Life Sci. 2005 Apr;62(7-8):751-9. doi: 10.1007/s00018-004-4506-0. Cell Mol Life Sci. 2005. PMID: 15868400 Review.
Cited by
- Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure.
Gupta MP. Gupta MP. J Mol Cell Cardiol. 2007 Oct;43(4):388-403. doi: 10.1016/j.yjmcc.2007.07.045. Epub 2007 Jul 21. J Mol Cell Cardiol. 2007. PMID: 17720186 Free PMC article. Review. - Roles of NAD (+) , PARP-1, and Sirtuins in Cell Death, Ischemic Brain Injury, and Synchrotron Radiation X-Ray-Induced Tissue Injury.
Ying W. Ying W. Scientifica (Cairo). 2013;2013:691251. doi: 10.1155/2013/691251. Epub 2013 Dec 10. Scientifica (Cairo). 2013. PMID: 24386592 Free PMC article. Review. - Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Pacher P, Szabó C. Pacher P, et al. Cardiovasc Drug Rev. 2007 Fall;25(3):235-60. doi: 10.1111/j.1527-3466.2007.00018.x. Cardiovasc Drug Rev. 2007. PMID: 17919258 Free PMC article. Review. - Novel modulators of poly(ADP-ribose) polymerase.
Szabo C, Pacher P, Swanson RA. Szabo C, et al. Trends Pharmacol Sci. 2006 Dec;27(12):626-30. doi: 10.1016/j.tips.2006.10.003. Epub 2006 Oct 19. Trends Pharmacol Sci. 2006. PMID: 17055069 Free PMC article. - The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1.
Feng XJ, Gao H, Gao S, Li Z, Li H, Lu J, Wang JJ, Huang XY, Liu M, Zou J, Ye JT, Liu PQ. Feng XJ, et al. Br J Pharmacol. 2015 Jun;172(11):2852-63. doi: 10.1111/bph.13091. Epub 2015 Mar 26. Br J Pharmacol. 2015. PMID: 25625556 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases